atopic


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

a·top·ic

 (ā-tŏp′ĭk)
adj.
Of, relating to, or caused by a hereditary predisposition to developing allergic reactions, such as hay fever, asthma, or urticaria, after exposure to specific antigens such as pollen, food, and insect venoms.
[From Greek atopiā, unusualness, from atopos, out of the way : a-, not; see a-1 + topos, place.]
at′o·py (ăt′ə-pē) n.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

atopic

(əˈtɒpɪk)
adj
(Physiology) immunol of or relating to hereditary hypersensitivity to certain allergens
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Translations

a·top·ic

a. atópico-a, rel. a la atopía.
English-Spanish Medical Dictionary © Farlex 2012

atopic

adj atópico
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
A pivotal Phase 3 trial evaluating Dupixent[R] (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints.
Sanofi - Sanofi : Dupixent[R] (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis - 6/8/2019
In this clinical trial, weekly subcutaneous, or SC, doses of KPL-716 resulted in a rapid and sustained reduction in pruritus throughout the 12-week treatment period but also a higher rate of atopic dermatitis flares.
Kiniksa announces interim results from Phase 1b KPL-716 trial
ENPNewswire-August 7, 2019--Sanofi - Dupixent showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
Sanofi - Dupixent showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
M2 PHARMA-August 6, 2019-Regeneron Pharmaceuticals Inc announces EC marketing approval for Dupixent (dupilumab) for moderate-to-severe atopic dermatitis
Regeneron Pharmaceuticals Inc announces EC marketing approval for Dupixent (dupilumab) for moderate-to-severe atopic dermatitis
Global Banking News-August 6, 2019-Regeneron Pharmaceuticals Inc announces EC marketing approval for Dupixent (dupilumab) for moderate-to-severe atopic dermatitis
Regeneron Pharmaceuticals Inc announces EC marketing approval for Dupixent (dupilumab) for moderate-to-severe atopic dermatitis
M2 EQUITYBITES-August 6, 2019-Regeneron Pharmaceuticals Inc announces EC marketing approval for Dupixent (dupilumab) for moderate-to-severe atopic dermatitis
Regeneron Pharmaceuticals Inc announces EC marketing approval for Dupixent (dupilumab) for moderate-to-severe atopic dermatitis
CHICAGO -- Atopic dermatitis in adulthood was associated with a twofold increase in the risk of developing dementia late in life, based on results from a large longitudinal cohort study presented at the annual meeting of the Society for Investigative Dermatology.
Study finds link between atopic dermatitis, late-life dementia
Atopic dermatitis is a very common inflammatory skin disease whose incidence is increasing worldwide and which has a significantly negative effect on the quality of life.
Lack of omalizumab efficacy in severe atopic dermatitis with extremely elevated IgE levels: two case reports and a literature review
Atopic dermatitis, also called atopic eczema, is one such skin condition that affects one in five children globally.
6 ways to manage dry and itchy skin in babies
6, 2018 (HealthDay News) -- The prevalence of atopic dermatitis is 7.3 percent among U.S.
Prevalence of Atopic Dermatitis 7.3 Percent in U.S. Adults; Patients with AD and more severe disease have higher scores on dermatology life quality index
Objective: To compare the efficacy and safety of topical betamethasone valerate 0.1% with narrowband ultraviolet B (NB-UVB) therapy in atopic dermatitis.
Comparison of efficacy and safety of topical betamethasone valerate 0.1% with narrowband-UVB in atopic dermatitis

Dictionary browser ?
Full browser ?